|
Hemangiosarcoma
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells.
|
25252913 |
2014 |
|
Hemangiosarcoma
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
Recurrent PTPRB and PLCG1 mutations in angiosarcoma.
|
24633157 |
2014 |
|
Hemangiosarcoma
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
Recurrent mutations in PTPRB and PLCG1 were identified in angiosarcomas.
|
24795022 |
2014 |
|
Hemangiosarcoma
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
In one case, we identified a mutation in PLCG1 identical to a mutation observed previously in this gene in human visceral AS.
|
29190660 |
2017 |
|
Hemangiosarcoma
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
The genetic bases of these tumors have been partially revealed in recent studies reporting genetic alterations such as amplifications of MYC (primarily in radiation-associated angiosarcomas), inactivating mutations in PTPRB and R707Q hotspot mutations of PLCG1.
|
26440310 |
2015 |
|
Lymphoma, T-Cell, Cutaneous
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
This study functionally interrogated nine PLCG1 mutations (p.R48W, p.S312L, p.D342N, p.S345F, p.S520F, p.R1158H, p.E1163K, p.D1165H, and the in-frame indel p.VYEEDM1161V) identified in Sézary Syndrome, the leukemic variant of CTCL.
|
31376383 |
2020 |
|
Lymphoma, T-Cell, Cutaneous
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
This new study finds that only 3-5% of the CTCL tumor genomes (mycosis fungoides and Sézary syndrome) harbor PLCG1 mutations.
|
26269406 |
2015 |
|
Lymphoma, T-Cell, Cutaneous
|
0.350 |
Biomarker
|
disease |
BEFREE |
Subsequently, 13 hub genes including CFLAR, GCNT2, IFNG, IL17A, IL22, MIP, PLCG1, PTH, PTPN6, REG1A, SNAP25, SUPT7L, and TP63 were shown to be related to cutaneous T-cell lymphoma (CTCL) and adult T-cell lymphoma/leukemia (ATLL).In summary, in addition to the reported genes (IL17F, PLCG1, IFNG, and PTH) in CTCL/ATLL, the other high instable genes may serve as novel biomarkers for the regulation of the biological processes and molecular mechanisms of CTLT (MF/SS).
|
29794791 |
2018 |
|
Lymphoma, T-Cell, Cutaneous
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Recent evidence suggests that disturbances in specific intracellular signalling pathways, such as RAS-mitogen-activated protein kinase, T-cell receptor (TCR)-phospholipase C gamma 1 (PLCG1)-nuclear factor of activated T cells (NFAT) and Janus kinase (JAK)-signal transducer and activator of transcription (STAT), may play an essential role in the pathogenesis of CTCL.
|
31049933 |
2020 |
|
Lymphoma, T-Cell, Cutaneous
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Thus, increased proliferative and survival mechanisms in CTCL may partially depend on the acquisition of somatic mutations in PLCG1 and other genes that are essential for normal T-cell differentiation.
|
24497536 |
2014 |
|
Sezary Syndrome
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
This study functionally interrogated nine PLCG1 mutations (p.R48W, p.S312L, p.D342N, p.S345F, p.S520F, p.R1158H, p.E1163K, p.D1165H, and the in-frame indel p.VYEEDM1161V) identified in Sézary Syndrome, the leukemic variant of CTCL.
|
31376383 |
2020 |
|
Sezary Syndrome
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Mutations in PLCG1 were detected in 11% of tumors including novel variants not previously described in SS.
|
27121473 |
2016 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism.
|
11409699 |
2001 |
|
Adult T-Cell Lymphoma/Leukemia
|
0.310 |
Biomarker
|
disease |
BEFREE |
Subsequently, 13 hub genes including CFLAR, GCNT2, IFNG, IL17A, IL22, MIP, PLCG1, PTH, PTPN6, REG1A, SNAP25, SUPT7L, and TP63 were shown to be related to cutaneous T-cell lymphoma (CTCL) and adult T-cell lymphoma/leukemia (ATLL).In summary, in addition to the reported genes (IL17F, PLCG1, IFNG, and PTH) in CTCL/ATLL, the other high instable genes may serve as novel biomarkers for the regulation of the biological processes and molecular mechanisms of CTLT (MF/SS).
|
29794791 |
2018 |
|
Malignant Neoplasms
|
0.160 |
Biomarker
|
group |
BEFREE |
Phospholipase Cγ1 links inflammation and tumorigenesis in colitis-associated cancer.
|
29464031 |
2018 |
|
Malignant Neoplasms
|
0.160 |
Biomarker
|
group |
BEFREE |
The enzyme phospholipase C gamma 1 (PLCγ1) has been identified as a potential drug target of interest for various pathological conditions such as immune disorders, systemic lupus erythematosus, and cancers.
|
31548507 |
2019 |
|
Malignant Neoplasms
|
0.160 |
Biomarker
|
group |
BEFREE |
Taken together, our data suggest that (i) UCP2 is an important regulator of mitochondrial redox status and lipid signaling; (ii) hydrogen peroxide might mediate UCP2's tumor promoting activity; and (iii) pharmacological disruption of PLCγ-1 and/or hydrogen peroxide may have clinical utility for UCP2 overexpressed cancers.
|
28574619 |
2017 |
|
Malignant Neoplasms
|
0.160 |
Biomarker
|
group |
BEFREE |
We further show that this novel PDK1-PLCγ1 pathway is important for cancer cell invasion.
|
22454520 |
2012 |
|
Malignant Neoplasms
|
0.160 |
Biomarker
|
group |
BEFREE |
PLCγ1 activities play an important role in the metastasis of gastric adenocarcinoma, and may serve as a potential therapeutic target in this type of cancer.
|
25308733 |
2014 |
|
Malignant Neoplasms
|
0.160 |
GeneticVariation
|
group |
BEFREE |
Furthermore, in tandem SH2 and γSA constructs, molecular dynamics and NMR results show that the Arg687Trp mutant in PLCγ1 (equivalent to the cancer mutation Arg665Trp in PLCγ2) perturbs the dynamic allosteric pathway.
|
29972810 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased PLCG1 expression in tumor tissues was remarkably correlated with poor clinical features of HCC.
|
30623526 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, analysis of 60 breast cancer patients' tissues revealed an increase of PLCgamma1 expression in metastasis compared with the primary tumor in 50% of tissues analyzed.
|
19074886 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the Akt/Bad, Akt/S6, and ERK/Bad signal axes were involved in PLCγ1-mediated tumor growth and metastasis of human gastric adenocarcinoma.
|
26811493 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our study provides a mechanistic basis for the role for the PLCγ1-PKCγ pathway in regulating Hsp90α plasma membrane translocation, which facilitates tumor cell motility and promotes tumor metastasis.
|
24899266 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also propose a novel mechanism by which the tumor microenvironment could contribute to T cell dysfunction and shorter survival, i.e., diminished expression levels of essential signaling proteins, including STAT5B, PLCγ1 and NFATc2.
|
29721385 |
2018 |